NasdaqCM - Delayed Quote • USD
ESSA Pharma Inc. (EPIX)
At close: April 23 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -0.19 | -0.21 | -0.79 | -1.05 |
| Low Estimate | -0.24 | -0.28 | -1 | -2.1 |
| High Estimate | -0.15 | -0.15 | -0.6 | -0.61 |
| Year Ago EPS | -0.16 | -0.17 | -0.6 | -0.79 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 3 | 4 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.2 | -0.19 | -0.21 | -0.17 |
| EPS Actual | -0.16 | -0.17 | -0.12 | -0.14 |
| Difference | 0.04 | 0.02 | 0.09 | 0.03 |
| Surprise % | 20.00% | 10.50% | 42.90% | 17.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.19 | -0.21 | -0.79 | -1.05 |
| 7 Days Ago | -0.19 | -0.21 | -0.79 | -1.05 |
| 30 Days Ago | -0.19 | -0.21 | -0.79 | -1.05 |
| 60 Days Ago | -0.19 | -0.21 | -0.79 | -1.05 |
| 90 Days Ago | -0.2 | -0.22 | -0.8 | -1.21 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | EPIX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -18.80% | -- | -- | 0.40% |
| Next Qtr. | -23.50% | -- | -- | 9.90% |
| Current Year | -31.70% | -- | -- | 4.30% |
| Next Year | -32.90% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Oppenheimer: Outperform to Outperform | 12/13/2023 |
| Reiterates | Oppenheimer: Outperform to Outperform | 8/9/2023 |
| Maintains | Piper Sandler: Overweight | 5/12/2022 |
| Maintains | Oppenheimer: Outperform | 8/17/2021 |
| Initiated | Piper Sandler: Overweight | 3/4/2021 |
| Maintains | HC Wainwright & Co.: Buy | 2/25/2021 |
Related Tickers
MSCL.TO Satellos Bioscience Inc.
0.4900
+2.08%
ENGN enGene Holdings Inc.
15.26
+3.11%
CRVS Corvus Pharmaceuticals, Inc.
1.5300
+6.25%
BETR.CN BetterLife Pharma Inc.
0.1050
0.00%
RPTX Repare Therapeutics Inc.
3.3600
+3.07%
MDNAF Medicenna Therapeutics Corp.
1.1400
+3.07%
ANTX AN2 Therapeutics, Inc.
2.3700
+0.42%
ANVS Annovis Bio, Inc.
11.88
+3.39%
CGTX Cognition Therapeutics, Inc.
2.0000
+7.53%
COGT Cogent Biosciences, Inc.
6.96
-2.25%